Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
De Castro N, Braun J, Charreau I, Pialoux G, Cotte L, Katlama C, Raffi F, Weiss L, Meynard JL, Yazdanpanah Y, Delaugerre C, Madelaine-Chambrin I, Aboulker JP, Molina JM; EASIER ANRS 138 study group. De Castro N, et al. Among authors: delaugerre c. Clin Infect Dis. 2009 Oct 15;49(8):1259-67. doi: 10.1086/605674. Clin Infect Dis. 2009. PMID: 19757993 Clinical Trial.
JC virus variant associated with cerebellar atrophy in a patient with AIDS.
Roux D, Bouldouyre MA, Mercier-Delarue S, Seilhean D, Zagdanski AM, Delaugerre C, Simon F, Molina JM, Legoff J. Roux D, et al. Among authors: delaugerre c. J Clin Microbiol. 2011 Jun;49(6):2196-9. doi: 10.1128/JCM.02057-10. Epub 2011 Mar 23. J Clin Microbiol. 2011. PMID: 21430099 Free PMC article.
Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial.
Goldwirt L, Braun J, de Castro N, Charreau I, Barrail-Tran A, Delaugerre C, Raffi F, Lascoux-Combe C, Aboulker JP, Taburet AM, Molina JM. Goldwirt L, et al. Among authors: delaugerre c. Antimicrob Agents Chemother. 2011 Jul;55(7):3613-5. doi: 10.1128/AAC.01827-10. Epub 2011 May 16. Antimicrob Agents Chemother. 2011. PMID: 21576452 Free PMC article.
Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
Gallien S, Braun J, Delaugerre C, Charreau I, Reynes J, Jeanblanc F, Verdon R, de Truchis P, May T, Madelaine-Chambrin I, Aboulker JP, Molina JM; EASIER ANRS 138 Study Group. Gallien S, et al. Among authors: delaugerre c. J Antimicrob Chemother. 2011 Sep;66(9):2099-106. doi: 10.1093/jac/dkr269. Epub 2011 Jun 28. J Antimicrob Chemother. 2011. PMID: 21712241 Clinical Trial.
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Pavie J, Porcher R, Torti C, Medrano J, Castagna A, Valin N, Rusconi S, Ammassari A, Ghosn J, Delaugerre C, Molina JM; NEAT Unboosted Atazanavir Cohort Study Group. Pavie J, et al. Among authors: delaugerre c. J Antimicrob Chemother. 2011 Oct;66(10):2372-8. doi: 10.1093/jac/dkr316. Epub 2011 Aug 5. J Antimicrob Chemother. 2011. PMID: 21821627 Free article.
294 results